At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMNN Imunon, Inc.
Trading 10-29 13:41:45 EDT
0.8465
+0.0164
+1.98%
High0.8750Low0.8110Vol99.69K
Open0.8590D1 Closing0.8301Amplitude7.71%
Mkt Cap4.75MTradable Cap4.37MTotal Shares5.61M
T/O83.63KT/O Rate1.93%Tradable Shares5.17M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Imunon - May Appoint One Voxeldox Director and One Non-Voting Observer - SEC Filing
THOMSON REUTERS  ·  10-21
Imunon - May Appoint One Voxeldox Director and One Non-Voting Observer - SEC Filing
Imunon Agrees to Sell ThermoDox Rights to VoxelDox Therapeutics
Reuters  ·  10-21
Imunon Agrees to Sell ThermoDox Rights to VoxelDox Therapeutics
Imunon - to Receive Equity Stake, up to $16.50 Mln in Milestones, and Royalties
THOMSON REUTERS  ·  10-21
Imunon - to Receive Equity Stake, up to $16.50 Mln in Milestones, and Royalties
Imunon - Enters Agreement to Sell Rights to Thermodox to Voxeldox
THOMSON REUTERS  ·  10-21
Imunon - Enters Agreement to Sell Rights to Thermodox to Voxeldox
Imunon Announces Strategic Sale of Thermodox®
THOMSON REUTERS  ·  10-21
Imunon Announces Strategic Sale of Thermodox®
Imunon - to Receive 4.76% Equity Interest in Voxeldox upon Financing Completion
THOMSON REUTERS  ·  10-21
Imunon - to Receive 4.76% Equity Interest in Voxeldox upon Financing Completion
Imunon - Deal Closing Contingent on Voxeldox Completing $2.50 Mln Financing for Phase 1 Glioblastoma Trial
THOMSON REUTERS  ·  10-21
Imunon - Deal Closing Contingent on Voxeldox Completing $2.50 Mln Financing for Phase 1 Glioblastoma Trial
Imunon - Eligible for 3.5%-6% Tiered Royalties on Net Sales of Thermodox Products
THOMSON REUTERS  ·  10-21
Imunon - Eligible for 3.5%-6% Tiered Royalties on Net Sales of Thermodox Products
Imunon CEO Stacy Lindborg Joins Maxim Growth Summit Oncology Panel
Reuters  ·  10-08
Imunon CEO Stacy Lindborg Joins Maxim Growth Summit Oncology Panel
Imunon Converts USD 1.2 Million Debt into Newly Issued Preferred Shares
Reuters  ·  09-29
Imunon Converts USD 1.2 Million Debt into Newly Issued Preferred Shares
Imunon - Enters Exchange Agreement with Streeterville Capital on Sept 28, 2026 - SEC Filing
THOMSON REUTERS  ·  09-29
Imunon - Enters Exchange Agreement with Streeterville Capital on Sept 28, 2026 - SEC Filing
Imunon - Exchanges $1.20 Mln A-1 Note for 120 Series B Preferred Shares at $10,000 Per Share - SEC Filing
THOMSON REUTERS  ·  09-29
Imunon - Exchanges $1.20 Mln A-1 Note for 120 Series B Preferred Shares at $10,000 Per Share - SEC Filing
Imunon - Converts $1.20 Mln of Debt into Series B Preferred Stock
THOMSON REUTERS  ·  09-29
Imunon - Converts $1.20 Mln of Debt into Series B Preferred Stock
Imunon Issues 120 Series B Preferred Shares in Unregistered Sale Under Note Exchange
Reuters  ·  09-29
Imunon Issues 120 Series B Preferred Shares in Unregistered Sale Under Note Exchange
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN) and Imunon (IMNN)
TIPRANKS  ·  09-25
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN) and Imunon (IMNN)
Imunon Highlights 14.7-Month Overall Survival Gain in Phase 2 IMNN-001 Ovarian Cancer Study as Phase 3 Trial Advances
Reuters  ·  09-24
Imunon Highlights 14.7-Month Overall Survival Gain in Phase 2 IMNN-001 Ovarian Cancer Study as Phase 3 Trial Advances
Imunon - Targets Ovation 3 Enrollment Completion in Q1 2029
THOMSON REUTERS  ·  09-24
Imunon - Targets Ovation 3 Enrollment Completion in Q1 2029
Imunon Makes the Frontline Case for Phase 3 Imnn-001 Study: 14.7-Month Os Signal, Historical Il-12 Safety Barriers Overcome, Enrolling Ahead of Plan
THOMSON REUTERS  ·  09-24
Imunon Makes the Frontline Case for Phase 3 Imnn-001 Study: 14.7-Month Os Signal, Historical Il-12 Safety Barriers Overcome, Enrolling Ahead of Plan
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
GlobeNewswire  ·  09-24
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
Imunon - Idmc Recommends Phase 2 Mrd Study Continue Without Modification After Safety Review
THOMSON REUTERS  ·  09-22
Imunon - Idmc Recommends Phase 2 Mrd Study Continue Without Modification After Safety Review

Introduction

Company Name.
Imunon, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Issue price:
--